Adiposity in Chinese people with type 1 diabetes  

作　　者：Nian-Wei Wu Xia-Fei Lyu Zhen-Mei An She-Yu Li 

机构地区：[1]Department of Endocrinology and Metabolism,West China Hospital,Sichuan University,Chengdu 610041,Sichuan Province,China [2]Department of Radiology,West China Hospital,Sichuan University,Chengdu 610041,Sichuan Province,China [3]Department of Guideline and Rapid Recommendation,Chinese Evidence-based Medicine Center,Cochrane China Center and MAGIC China Center,West China Hospital,Sichuan University,Chengdu 610041,Sichuan Province,China

出　　处：《World Journal of Diabetes》2024年第7期1404-1408,共5页世界糖尿病杂志（英文版）（电子版）

基　　金：Supported by 1.3.5 Project for Disciplines of Excellence,West China Hospital,Sichuan University,No.ZYYC24001.

摘　　要：Adiposity,synonymous with obesity,is prevalent among both children and adults with type 1 diabetes in China.Recent literature underscored the pathophysiological and socioeconomic factors associated with adiposity,and consistently highlighted its impact on cardiovascular,kidney,and metabolic diseases among Chinese individuals with type 1 diabetes.Addressing and managing adiposity in individuals with type 1 diabetes are complicated and entail comprehensive approaches including lifestyle modifications,cognitive-behavioral therapy,insulin dose titration,and other diabetes treatment medications.The condition calls for coordination among policymakers,researchers,clinicians,and patients.

关 键 词：Type 1 diabetes China Metabolic syndrome OBESITY Anti-obesity medications 

分 类 号：R587.1[医药卫生—内分泌]